title: Biomarker classification, validation, and what to look for in 2017 and beyond.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: John W
authors.initials: JW
authors.lastname: Davis
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood / Q000145:classification*; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D014571:Urologic Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor